The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Gilead Sciences, Inc (NASDAQ: GILD) closed at $121.36 in the last session, up 2.59% from day before closing price of $118.3. In other words, the price has increased by $2.59 from its previous closing price. On the day, 6.04 million shares were traded. GILD stock price reached its highest trading level at $121.99 during the session, while it also had its lowest trading level at $118.22.
Ratios:
We take a closer look at GILD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.43. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.03.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $140.
Daiwa Securities Upgraded its Neutral to Outperform on August 19, 2025, while the target price for the stock was maintained at $128.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 29 ’25 when O’Day Daniel Patrick sold 10,000 shares for $124.83 per share. The transaction valued at 1,248,272 led to the insider holds 566,698 shares of the business.
DANIEL O’DAY bought 10,000 shares of GILD for $1,248,272 on Dec 29 ’25. On Dec 15 ’25, another insider, Dickinson Andrew D, who serves as the Chief Financial Officer of the company, sold 3,000 shares for $122.00 each. As a result, the insider received 366,000 and left with 153,503 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 150584328192 and an Enterprise Value of 166935871488. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.80, and their Forward P/E ratio for the next fiscal year is 13.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.18 while its Price-to-Book (P/B) ratio in mrq is 7.00. Its current Enterprise Value per Revenue stands at 5.739 whereas that against EBITDA is 11.809.
Stock Price History:
The Beta on a monthly basis for GILD is 0.37, which has changed by 0.3271259 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $128.70, while it has fallen to a 52-week low of $88.57. The 50-Day Moving Average of the stock is -1.12%, while the 200-Day Moving Average is calculated to be 6.56%.
Shares Statistics:
According to the various share statistics, GILD traded on average about 6.94M shares per day over the past 3-months and 6160060 shares per day over the past 10 days. A total of 1.24B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.21% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for GILD as of 1765756800 were 21650110 with a Short Ratio of 3.12, compared to 1763078400 on 17007031. Therefore, it implies a Short% of Shares Outstanding of 21650110 and a Short% of Float of 1.7500000000000002.
Dividends & Splits
The forward annual dividend rate for GILD is 3.16, which was 3.14 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.026542688. The stock’s 5-year Average Dividend Yield is 3.79. The current Payout Ratio is 805.23% for GILD, which recently paid a dividend on 2025-12-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 2013-01-28 when the company split stock in a 2:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 21.0 different market analysts. The consensus estimate for the next quarter is $2.03, with high estimates of $2.19 and low estimates of $1.85.
Analysts are recommending an EPS of between $8.43 and $8.05 for the fiscal current year, implying an average EPS of $8.16. EPS for the following year is $8.76, with 28.0 analysts recommending between $9.95 and $6.38.
Revenue Estimates
According to 19 analysts,. The current quarter’s revenue is expected to be $7.67B. It ranges from a high estimate of $8.2B to a low estimate of $6.95B. As of. The current estimate, Gilead Sciences, Inc’s year-ago sales were $7.57BFor the next quarter, 19 analysts are estimating revenue of $7.04B. There is a high estimate of $7.25B for the next quarter, whereas the lowest estimate is $6.9B.
A total of 25 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.72B, while the lowest revenue estimate was $28.6B, resulting in an average revenue estimate of $29.21B. In the same quarter a year ago, actual revenue was $28.75BBased on 27 analysts’ estimates, the company’s revenue will be $30.16B in the next fiscal year. The high estimate is $31.25B and the low estimate is $28.72B.
